CDK4 and neoplasm: This preclinical activity, along with the objective responses observed in patients with prior CDK4/6i therapy treated with elacestrant in a phase 1 clinical trial [43], suggests that ER-driven tumor growth can be retained in patients that have been previously treated with CDK4/6i and that the clinical evaluation of an ER-targeted agent, such as elacestrant, is warranted.